Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 9Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Melanoma, Cutaneous Malignant 1

Interventions

durvalumab 3abemaciclib 3Fulvestrant 3Cisplatin 3ribociclib 2pembrolizumab 2palbociclib 2Pemetrexed 2Nivolumab 2Letrozole 2Carboplatin 2Bevacizumab 2Anastrozole 2130-nm albumin-bound paclitaxel 2selpercatinib 1selinexor 1repotrectinib 1relatlimab 1relacorilant 1olaparib 1gallium 68 PSMA-11 1exemestane 1enfortumab vedotin 1elacestrant 1darolutamide 1cemiplimab 1atezolizumab 1Tamoxifen 1Sunitinib 1STX-478 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × relatlimab × 90 days × Clear all
NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡